ArticleQuantitative imaging in medicine and surgery2024
Mean liver density independently predicts therapeutic response and liver-related mortality in patients with primary biliary cholangitis.
Article in Quantitative imaging in medicine and surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia, myosteatosis, and sarcopenic obesity are known to adversely affect nutritional status and quality of life in cirrhotic patients. However, there is limited research on these conditions in individuals with primary biliary cholangitis (PBC). This study aims to identify risk factors for sarcopenia, myosteatosis, and sarcopenic obesity in PBC patients and to investigate their association with therapeutic outcomes and liver-related mortality. Furthermore, this research aims to uncover novel imaging-based risk factors that may influence biochemical response rates and mortality risk. Methods: In this retrospective study, patients with PBC were enrolled. Sarcopenia and myosteatosis were defined using the third lumbar vertebra (L3) skeletal muscle index (SMI) and skeletal muscle density (SMD) obtained from computed tomography (CT) imaging. The prognosis of PBC patients can be accurately evaluated using the PARIS I criteria. Results: The study included 117 PBC patients, of whom 73 (62.4%) exhibited sarcopenia and 51 (43.6%) presented with myosteatosis. Seventeen (14.5%) patients were with sarcopenic obesity. The rate of biochemical response was 38.5%. During a mean follow-up period of 68 months, seven patients died. Patients with sarcopenia were older, with a lower body mass index (BMI) and a higher prevalence of myosteatosis, as well as lower visceral adipose tissue index (VATI) and subcutaneous adipose tissue index (SATI) levels (P<0.05). Patients with myosteatosis were older and had higher levels of albumin, SATI, and VATI (P<0.05). They also had a higher prevalence of sarcopenia and sarcopenia obesity (P<0.05). Multivariate analysis revealed that neither sarcopenia nor myosteatosis impacted the biochemical response rates or liver-related mortality in PBC patients. Conversely, mean liver density was identified as a significant risk factor for biochemical response and liver-related mortality (P<0.05). Conclusions: Mean liver density is an independent predictor for biochemical response and liver-related mortality in patients with PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.